Velan Capital Investment Management LP lowered its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 93.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 90,000 shares of the company's stock after selling 1,200,323 shares during the quarter. Context Therapeutics comprises 0.1% of Velan Capital Investment Management LP's holdings, making the stock its 27th biggest position. Velan Capital Investment Management LP owned 0.12% of Context Therapeutics worth $94,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Shay Capital LLC acquired a new stake in shares of Context Therapeutics during the fourth quarter worth $52,000. MPM Bioimpact LLC acquired a new position in Context Therapeutics in the fourth quarter valued at about $15,441,000. Millennium Management LLC raised its stake in Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after purchasing an additional 34,835 shares in the last quarter. Citadel Advisors LLC acquired a new position in Context Therapeutics in the fourth quarter valued at about $31,000. Finally, Allostery Investments LP acquired a new position in Context Therapeutics in the fourth quarter valued at about $998,000. Institutional investors and hedge funds own 14.03% of the company's stock.
Context Therapeutics Stock Down 0.8%
Context Therapeutics stock opened at $0.71 on Tuesday. Context Therapeutics Inc. has a 12-month low of $0.55 and a 12-month high of $2.75. The business's 50-day moving average price is $0.78 and its two-hundred day moving average price is $1.05. The stock has a market cap of $63.36 million, a PE ratio of -0.78 and a beta of 2.11.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). As a group, analysts expect that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms recently commented on CNTX. William Blair reaffirmed an "outperform" rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $6.00.
Get Our Latest Research Report on Context Therapeutics
Context Therapeutics Profile
(
Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
Want to see what other hedge funds are holding CNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Context Therapeutics Inc. (NASDAQ:CNTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
